tiprankstipranks

Zai Lab, Innoviva announce China NMPA approval for Xacduro

Zai Lab (ZLAB )and Innoviva (INVA) announced that China’s National Medical Products Administration, or NMPA, has approved Zai Lab’s New Drug Application (NDA) for Xacduro for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue